学术职务：

山东大学生活质量与公共政策研究中心专任研究员

山东大学公共卫生学院助理研究员

山东大学健康偏好研究中心研究员

研究方向：

健康相关生命质量、患者报告结局与疾病负担

主讲课程：

健康教育学、卫生政策学、药物经济学、环境与健康科学概论

学术兼职：

中国人体健康科技促进会药物政策研究工作委员会 委员

中国中医药研究促进会药物经济学与药物评价专委会 委员

中国中医药信息学会生命质量研究分会 理事

中国中医药信息学会中医药综合评价智能决策分会 理事

山东省药学会药物经济与政策专委会 委员

山东预防医学会卫生事业管理分会 委员

残疾人健康管理专业委员会 委员

主持承担的科研项目：

基于合作治理理论的公立医院补偿机制方案设计及实证研究，国家自然科学基金青年项目

合作治理视角下公立医院补偿机制方案设计研究，中国博士后科学基金面上项目

健康公平视角下罕见病医疗保障的国际范式与中国方案

国内外患者报告结局的应用现状与研究进展

中国成人SMA患者临床需求、诊疗偏好与健康相关生命质量研究

全球成人血友病患者的患者报告结局测量综述

发表论文：

Clinical, humanistic, and economic burden of haemophilia A in China: findings from a real-world survey. Orphanet Journal of Rare Diseases.2025.

Health-related quality of life and correlation with clinical severity in patients with acne: a cross-sectional study at a single centre in China. BMJ Open.2025.

The Humanistic and Economic Burden of COPD Patients in Urban China: A Propensity Score Matching Study. International Journal Of Chronic Obstructive Pulmonary Disease.2025.

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. Therapeutic Advances in Gastroenterology.2025.

Comparison of EQ-5D-Y-3L utility scores using nine country-specific value sets in Chinese adolescents. PharmacoEconomics.2024.

Correlation between clinical severity and patient-reported health-related quality of life in rheumatoid arthritis: a cross-sectional study, BMJ Open.2024.

Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced esophageal squamous cell carcinoma: a systematic review and economic evaluation. Therapeutic Advances in Gastroenterology. 2024.

Health-related quality of life and its changes of the Tibetan population in China: based on the 2013 and 2018 National Health Services Surveys. BMJ Open 2023.

Psychometric properties and comparison of four health utility approaches among myopia patients in China. Health Qual Life Outcomes. 2023.

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol. 2023.

Responsiveness and minimal clinically important difference of EQ-5D-5L in patients with coronary heart disease after percutaneous coronary intervention: A longitudinal study. Front Cardiovasc Med. 2023.

Health-Related Quality of Life and Its Influencing Factors in Patients with Coronary Heart Disease in China. Patient Prefer Adherence. 2022.

Factors Associated with Medication Adherence Among Patients with Severe Mental Disorders in China: A Propensity Score Matching Study. Patient Prefer Adherence. 2020.